Eylea HD Market Report 2026

Eylea HD Market Overview

• The Eylea HD market growth in the historic period has been driven by high prevalence of retinal disorders, frequent injection burden of earlier therapies • Market expansion is supported by rising diabetic retinopathy cases, demand for long acting formulations • Growth Driver: Growing Prevalence Of Eye Disorders And Its Effect On Treatment Development • Market Trend: Regeneron Pharmaceuticals Receives FDA Approval For Eylea HD To Enhance Retinal Disease Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Eylea HD Market?

Eylea HD is an advanced formulation of the drug aflibercept, a vascular endothelial growth factor (VEGF) inhibitor used to treat specific retinal diseases. It is delivered via intravitreal injection and contains a higher dosage (8 mg) than standard Eylea (2 mg). This higher dose allows for extended treatment intervals, reducing the need for frequent injections while maintaining similar efficacy and safety profiles. The main types of indications in eylea HD are wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, and macular edema. Wet age-related macular degeneration (wet AMD) is a chronic eye disorder caused by abnormal blood vessel growth beneath the retina, leading to vision loss. It is distributed through various channels such as hospital pharmacies, specialty pharmacies, and online pharmacies, catering to various end users such as hospitals, clinics, ambulatory surgery centers (ASCs), and home care providers.

What Is The Eylea HD Market Growth Forecast?

The growth in the forecast period can be attributed to rising diabetic retinopathy cases, demand for long acting formulations, advancements in ocular drug delivery, increasing elderly population, expansion of outpatient eye care centers. Major trends in the forecast period include shift toward extended dosing intervals, rising demand for high dose anti vegf therapies, focus on reducing injection frequency, growth in retinal disease management, improved patient compliance in ophthalmology.

Global Eylea HD Market Segmentation

1) By Indication: Wet Age-Related Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema 2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies 3) By End User: Hospitals, Clinics, Ambulatory Surgery Centers (ASCs), Home Care Providers

What Are The Drivers Of The Eylea HD Market?

The rising prevalence of eye disorders is expected to propel the growth of the eylea HD market going forward. Eye disorders encompass various conditions, such as refractive errors, cataracts, glaucoma, macular degeneration, diabetic retinopathy, and retinal diseases, that impair vision or cause discomfort. An aging population, increased screen time, environmental factors, genetic predisposition, and the growing incidence of chronic health conditions largely drive the rising prevalence of eye disorders. Eylea HD (aflibercept injection 8 mg) is a medication used to treat eye disorders involving abnormal blood vessel growth or fluid leakage in the retina. It is an updated, high-dose formulation of Eylea (aflibercept 2 mg). For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2024, 17.2% of Americans aged 40 and older, or about 20.5 million people, will have cataracts in at least one eye, with this number expected to rise to over 30 million by 2028. Therefore, the rising prevalence of eye disorders is driving the growth of the eylea HD industry. The rising adoption of personalized medicines is expected to propel the growth of the eylea HD market going forward. Personalized medicine tailors medical treatment to an individual's unique genetic, environmental, and lifestyle factors for more effective and safer therapies. The rising adoption of personalized medicines can be attributed to advancements in genomics, improved diagnostics, increased efficacy, reduced side effects, growing patient demand, regulatory support, and long-term cost-effectiveness. Eylea HD exemplifies personalized medicine by providing targeted, effective treatment for retinal diseases tailored to individual patient characteristics, advancing precision medicine in ophthalmology. For instance, in February 2024, the Personalized Medicine Coalition, a US-based organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approvals in 2022. Therefore, the rising adoption of personalized medicines is driving the growth of the eylea HD industry

Key Players In The Global Eylea HD Market

Major companies operating in the eylea hd market are Regeneron Pharmaceuticals Inc, Bayer AG

Global Eylea HD Market Trends and Insights

The key trend in the eylea HD market is developing innovative biologic medications to enhance treatment efficacy, improve patient outcomes, and reduce the frequency of injections. Biologic medications refer to drugs made from living organisms or their cells, designed to treat various diseases related to the immune system, cancer, and chronic conditions such as diabetes. For instance, in August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for Eylea HD (aflibercept) Injection 8 mg, a biologic medication designed to treat conditions such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). This approval highlights the company’s commitment to advancing treatment options that enhance efficacy, improve patient outcomes, and reduce the frequency of injections, ultimately benefiting patients with retinal diseases.

Regional Insights

North America was the largest region in the eylea HD market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Eylea HD Market?

The eylea HD market consists of sales of injections, delivery devices, companion diagnostic tools, single-dose vials, and biosimilars and generics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Eylea HD Market Report 2026?

The eylea hd market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the eylea hd industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.